Mariana Castanheira, PhD

CSO
Element

Disclosure(s): Melinta Therapeutics: Advisor/Consultant, Grant/Research Support

Poster(s):

• (P-1193) Activity of isavuconazole against contemporary Mucorales from a worldwide surveillance program
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1194) Activity of manogepix against mould isolates collected from the US in 2023
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1195) Activity of manogepix against surveillance yeast isolates collected from the United States in 2023
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1196) Geographic distribution, MIC testing, and susceptibility rates of Candida auris isolates collected in the United States since 2014
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1205) In vitro activity of EL219 (SF001) and amphotericin B agents against a collection of Candida and Aspergillus isolates collected in 2024
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1213) Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1214) In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1278) Activity of cefiderocol and comparator agents against carbapenem-resistant Enterobacterales, including molecularly characterized isolates recovered from United States hospitals in 2020–2024
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1279) Five-year trend analysis of carbapenem-resistant Enterobacterales, including isolates carrying metallo-β-lactamase genes in United States, Europe and adjacent regions during 2020–2024
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1286) In vitro Activity of Cefiderocol against Carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2024)
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1287) In Vitro Activity of Cefiderocol against Resistant Subsets of Pseudomonas aeruginosa collected from United States Hospitals during 2020–2024
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1313) A 10-year Trend on Antimicrobial Resistance of Pseudomonas aeruginosa from United States Medical Centers: Results from the INFORM Surveillance Program (2015-2024)
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1314) Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from Europe, Asia, and Latin America (2020-2024).
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1315) Activity of Aztreonam-avibactam and Ceftazidime-Avibactam against Enterobacterales and Pseudomonas aeruginosa Causing Infections in Immunosuppressed Patients from United States Medical Centers (2019-2024)
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1316) Activity of Aztreonam-Avibactam and Comparators against Difficult-To-Treat Resistant (DTR) Enterobacterales from United States Medical Centers (2020-2024).
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1317) Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents Tested against Enterobacterales from European Hospitals Analysed by Infection Type (2022-2024)
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1318) Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Stenotrophomonas maltophilia Isolates from Patients Hospitalized with Pneumonia in Europe, Latina America, and Asia (2020-2024).
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1319) Antimicrobial Activity of Aztreonam-Avibactam and Molecular Characterization of Enterobacterales Resistant to Ceftazidime-Avibactam and/or Meropenem-Vaborbactam from United States Medical Centers (2016-2024)
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1320) Antimicrobial susceptibility of S. maltophilia and B. cepacia species complex isolated from patients with pneumonia in United States hospitals (2022-2024).
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1332) Activity of aztreonam-avibactam tested against genetically characterized non-carbapenemase producing carbapenem-resistant Enterobacterales
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1333) Activity of Zosurabalpin and Comparator Antimicrobial Agents Tested Against Acinetobacter baumannii-calcoaceticus complex (ABC) Isolates Collected Worldwide in 2024.
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1340) Activity of Delafloxacin and Comparator Agents Against Bacterial Isolates From Patients with Diabetic Foot Infection in the United States and Europe (2017–2023)
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1697) Performance of the VITEK 2 with Advanced Expert System as a fast method for determination of antimicrobial susceptibility against 400 Enterobacterales isolates from North and Latin America (2022)
  Wednesday, October 22, 2025

  12:15 PM - 1:30 PM US ET